Brandon Capital Partners Pty Ltd.

About The Fund

Brandon Capital Partners is a specialized funds management business focused on the life science sphere, providing financial support to innovative ventures within the Education, BioTech, HealthTech (& Fitness), and Medical Devices (& Hospital Services) industries. With a comprehensive investment range of $4,000,000 to $50,000,000, they aim to generate substantial returns for Australia's leading superannuation funds via strategic investments. They engage closely with entrepreneurs to nurture and scale their businesses, thereby creating substantial value for the founders, their teams, and investors. Brandon Capital is deeply invested in health with the goal of developing cutting-edge medical innovations. They extend their capabilities from early-stage seed investment through to expansion capital, supporting life science companies from proof-of-concept right through to commercialization. Brandon Capital prides itself on its track record of raising successive funds that span the entirety of the life science venture investing spectrum and possesses a co-investment setup with their investors, ensuring substantial support capacity for their growing portfolio companies. Their investment philosophy is keen on early engagement, with a history of being the founding investor in most of their current portfolio companies. Their active portfolio encompasses ventures such as Perx, Pheon Therapeutics, TamoRx, NRG Therapeutics, Entact Bio, CatalYm, Myricx Bio, and Axelia Oncology. These companies are involved in a range of innovative undertakings from digitally-scaled care management programs and developing cancer therapeutics to creating novel payloads for ADCs and revolutionary treatments for neurodegenerative disorders. Brandon Capital Partners maintains a global presence with investors and venture partners across Australia, New Zealand, the United States, and the United Kingdom. The firm is headquartered in Melbourne, with additional offices in Sydney, San Francisco, and London.